Photo Credit: Gilaxia via Getty Images
To better control the Monkeypox outbreak, which the World Health Organization has now classified as having reached the highest level, the U.S. Food and Drug Administration stated on Tuesday that Monkeypox vaccines could now be given to a broader age group.
Children who are most vulnerable to the virus are allowed to take the vaccine, according to the notice. According to Dr. Peter Marks, director of the FDA’s vaccine section, children are now more likely to contract Monkeypox in recent weeks.
The injection of the vaccine between the layers of skin, or intradermal vaccination, is an option for adults. A five-fold increase in vaccination supply is now possible thanks to a new directive by the FDA. In the past, vaccines for Monkeypox were administered via subcutaneous injection, which necessitates a higher dosage due to the fact that the vaccine should be delivered beneath the skin.
It just takes a small amount of the vaccines for intradermal injections, according to Robert Fenton, the White House’s response coordinator for Monkeypox. Four hundred thousand vials of vaccines intended for subcutaneous injection are equivalent to approximately 2 million injections of the vaccine given intravenously, according to assessments and calculations.
But since further research is required before the FDA and the White House response team can approve intradermal injections for people of lower age, minors would only be able to receive injections through the subcutaneous route. Fenton claims that treating children more so than treating adults is a challenging procedure.
Read Also: Polio Case Confirmed in New York may be the First of Many, says New York State Health Official
Monkeypox vaccine manufacturer needs to deliver more
The Jynneos vaccine, made by Bavarian Nordic, is the only type of monkeypox vaccination that has received FDA approval. Located in Denmark, the biotech firm has been in contact with the U.S. government to address the supply shortage of Monkeypox vaccines.
Biden previously worked with Bavarian Nordic to enhance the availability of Monkeypox vaccines in the U.S. in response to complaints from hospitals and health authorities about lengthier lines caused by a shortage of Jynneos vials. Bavarian Nordic declares that further vaccination injections are on their way and will arrive by the end of the current year, pending FDA approval.
The fact that there haven’t been any recent cases of smallpox reported in the nation or a monkeypox outbreak prior to the current one, Dr. Robert Calliff, the Commissioner of the FDA, stated that it’s impossible for scientists to know for sure how well the vaccination protects against the Monkeypox virus. Using only the data on immunological responses, the FDA gave Bavarian Nordic the all-clear in 2019.
The Centers for Disease Control and Prevention announced that it would carry out research and assessments to examine the vaccine’s effects in a real-world setting. According to the CDC’s Dr. Rochelle Walensky, their study will continue when the vaccine is given out.
Read Also: Senate OKs Bill Granting Billions of Funding for Health and Climate
More trouble as supply runs low amid an increasing number of cases
More cases are being reported every day as the virus spreads to other nations. The supply of vaccine injections is running low as a result of the ongoing demand. The government is having trouble reassuring the doctors’ and residents’ concerns about the supply of vaccines because there is only one supplier of the Monkeypox vaccines, Bavarian Nordic.
Including Washington, D.C., and Puerto Rico, the CDC has long documented cases of Monkeypox in 49 U.S. states. Just last week, the Department of Health and Human Services classified the monkeypox outbreak as a public health emergency.
Although there are not many fatalities associated with Monkeypox, many patients nevertheless seek care due to the painful lesions they form. The WHO estimates that there are already 9,000 confirmed cases of Monkeypox, despite the fact that no deaths have been reported in the U.S. to date.
Skin-to-skin contact, particularly during sex, is the primary method of transmission for Monkeypox. In addition, public health authorities advise people to avoid crowded places because the virus can spread through close physical contact.
Monkeypox does not discriminate against gender, according to medical professionals, even when around 98% of documented cases are of gay and bisexual men. If the virus is not stopped soon, there is a strong likelihood that it may spread to a wider population.
Source: CNBC
